ArticleBreast cancer research : BCR2025

Pharmacovigilance study of adverse reactions of anti-HER-2 drugs for the treatment of HER-2-positive breast cancer based on the FAERS database.

Jinming Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.